



# PREVALENCE OF MBL PRODUCING PSEUDOMONAS AERUGINOSA IN TERTIARY CARE HOSPITAL

Yamuna Devi V.R<sup>1\*</sup>, Arunachala D Edukondalu<sup>2</sup>

<sup>1</sup>Assistant Professor, Department of Microbiology, Bhaarith Medical College and Hospital, Chennai, (Affiliated to Bhaarith University, Chennai), Tamil Nadu, India

<sup>2</sup>Professor, Department of Anesthesia, Bhaarith Medical College and Hospital, Chennai, (Affiliated to Bhaarith University, Chennai), Tamil Nadu, India

## Abstract

*Pseudomonas aeruginosa*, a notorious nosocomial pathogen, exhibits intrinsic resistance to various antibiotics. The emergence of Metallo- $\beta$ -lactamase (MBL) production in *P. aeruginosa* poses a serious threat to the efficacy of carbapenems, crucial antibiotics in treating severe infections. Tertiary care hospitals, due to their complexity and patient diversity, are potential reservoirs for multidrug-resistant organisms, making the investigation of MBL prevalence imperative for informed therapeutic interventions. This study aims to determine the prevalence of MBL-producing *P. aeruginosa* in a tertiary care hospital, elucidating the epidemiology, antibiotic sensitivity patterns, and potential implications for patient outcomes. Clinical isolates of *P. aeruginosa* will be collected seventy samples from diverse hospital wards over two months. The presence of MBL will be assessed using established phenotypic methods, and antibiotic sensitivity profiles will be determined. Statistical analyses will be employed to evaluate the prevalence rates and associations. The percentage and Mean  $\pm$ SD were used to express the data. The study anticipates revealing the frequency of MBL production in *P. aeruginosa* isolates, providing insights into the distribution across hospital wards. Antibiotic sensitivity patterns will be elucidated, emphasizing the potential impact on therapeutic strategies. Understanding the prevalence of MBL-producing *P. aeruginosa* in a tertiary care hospital setting is crucial for optimizing antimicrobial stewardship and infection control measures. The findings of this study are anticipated to contribute valuable insights into the current landscape of antibiotic resistance, guiding evidence-based interventions to enhance patient care and minimize the spread of multidrug-resistant pathogens in healthcare settings.

**Keywords:-** *Pseudomonas aeruginosa*, Metallo- $\beta$ -lactamase (MBL), Prevalence, Antibiotic resistance, Antibiotic sensitivity patterns, Multidrug-resistant organisms.

Access this article online

Home page:  
www.mcmed.us/journal/abs

Quick Response code



Received: 25.04.22

Revised: 12.05.22

Accepted: 28.05.22

## INTRODUCTION

Infections caused by *Pseudomonas aeruginosa* have emerged as a significant public health concern, especially in healthcare settings where immunocompromised patients are more susceptible to opportunistic pathogens. *P. aeruginosa* is known for its intrinsic resistance to multiple antimicrobial agents, and the emergence of Metallo- $\beta$ -lactamase (MBL) production

in this bacterium further complicates treatment options [1-3]. MBLs are enzymes that confer resistance to carbapenems, a class of antibiotics often considered the last resort for treating severe bacterial infections. The prevalence of MBL-producing *P. aeruginosa* strains has become a focal point for research, as it poses a serious threat to the efficacy of available antibiotics [4-5].

Corresponding Author: Dr V R Yamuna Devi Email: yaminielumalai2004@yahoo.com

Understanding the prevalence of MBL production in *P. aeruginosa* is crucial for guiding empirical antibiotic therapy and implementing effective infection control measures in healthcare settings. Tertiary care hospitals, due to their complexity and the nature of patients they serve, are particularly susceptible to the spread of multidrug-resistant organisms. Therefore, investigating the prevalence of MBL-producing *P. aeruginosa* in a tertiary care hospital setting is essential for informing targeted interventions and ensuring optimal patient outcomes [6-7].

*Pseudomonas aeruginosa* is an opportunistic pathogen associated with nosocomial infections, and its ability to develop resistance to multiple antibiotics poses a serious challenge for clinicians. Carbapenems, such as imipenem and meropenem, are often considered the last line of defense against *P. aeruginosa* infections. However, the emergence of Metallo- $\beta$ -lactamase (MBL) production in *P. aeruginosa* strains compromises the efficacy of these critical antibiotics [8-9].

Tertiary care hospitals, being hubs for complex medical interventions and catering to a diverse patient population, are at an elevated risk of harboring antibiotic-resistant strains. The prevalence of MBL-producing *P. aeruginosa* in such settings can serve as a key indicator of the extent of antimicrobial resistance and guide the development of targeted therapeutic strategies [10-13].

This study aims to investigate the prevalence of MBL-producing *P. aeruginosa* in a tertiary care hospital, shedding light on the epidemiology of this resistance mechanism. The research will involve the analysis of clinical isolates to determine the frequency of MBL production, antibiotic sensitivity patterns, and the potential impact on patient outcomes. By identifying the prevalence of MBL-producing *P. aeruginosa* in a tertiary care setting, this study intends to contribute valuable insights for optimizing antimicrobial stewardship programs, enhancing infection control measures, and ultimately improving the quality of patient care.

## MATERIAL AND METHODS

This research was carried out in Bhaarith Medical College and Hospital, Chennai. It's an analytical, prospective research. The trial will last for two months. Number of samples: Seventy *P. aeruginosa* isolates at least.

### Qualifications for inclusion:

All *P. aeruginosa* isolates from patients hospitalized to tertiary care hospitals, spanning all age groups and genders, were included in this investigation.

### Criteria for exclusion:

Individuals visiting outpatient clinics (OPD) isolated from the same patients over and over again. Sputum,

bronchoalveolar lavage (BAL), endotracheal aspirates, urine, blood, wound swabs, and indwelling catheters were among the samples that were collected in fully aseptic circumstances.

Oxidase reaction, colony morphology on Blood agar and MacConkey's agar, pigment synthesis, citrate utilisation, sugar fermentation, TSI reaction, and polymyxin B sensitivity tests are used to identify *Pseudomonas aeruginosa* isolates.

Muller-Hinton agar plates were subjected to antimicrobial sensitivity testing using the Kirby-Bauer disc diffusion technique. The disc diffusion method was used to test the following antibiotics (Hi-Media, India): imipenem (10  $\mu$ g), gentamicin (10  $\mu$ g), netilmicin (30  $\mu$ g), polymyxin-B (300 units), colistin (10  $\mu$ g), and piperacillin/tazobactam (100  $\mu$ g/ 10  $\mu$ g). For quality control, *P. aeruginosa* ATCC 27853 was employed [14-15].

Comparing several phenotypic techniques for *P. aeruginosa* MBL production detection has also been done. Calculating percentages and basic ratios was the method used for statistical analysis. The percentage and Mean  $\pm$ SD were used to express the data.

### Imipenem (IMP)-EDTA combined disc test

The combined disc method was performed as described by Yong *et al.* A lawn culture of the test isolate will be prepared. After allowing it to dry for 5 minutes, two imipenem discs, one with 0.5 M EDTA and the other plain, were placed on the surface of the agar plate approximately 30 mm apart. The plates were incubated overnight at 37 °C. An increase in the zone diameter of  $\geq 7$  mm around imipenem+EDTA disc in comparison to imipenem disc alone indicated production of MBL.

### Imipenem-EDTA double disc synergy test (DDST)

The IMP-EDTA double disk synergy test was performed as described by Lee *et al.* (24) Test organisms were inoculated on to plates with Mueller Hinton agar as recommended by the CLSI. An imipenem (10  $\mu$ g) disc was placed 20 mm centre to centre from a blank disc containing 10  $\mu$ L of 0.5 M EDTA (750  $\mu$ g). Enhancement of the zone of inhibition in the area between imipenem and the EDTA disc in comparison with the zone of inhibition on the far side of the drug was interpreted as a positive result [16-17].

## RESULTS

The study was conducted in a tertiary care facility in January and February of 2022. The study was conducted to determine the frequency of MBL generation in *P. aeruginosa* isolates, their pattern of antibiotic sensitivity, and the corresponding mortality among infected patients in our hospital. Comparing several phenotypic techniques for *P. aeruginosa* MBL production

detection has also been done. The following tables and figures show the findings of the analysis and presentation.

Among all inpatients number of cases of *P. aeruginosa* infection was highest in surgical ward, followed by orthopedic wards.

*P. aeruginosa* strains were isolated most commonly from pus & exudates, followed by other samples.

Among the 70 patients harboring *P. aeruginosa* infection, 58(82.8%) were male and only 12 (17%) were female

All 49 imipenem resistant *P. aeruginosa* strains were recovered from male patients.

Out of total 70 isolates of *P. aeruginosa* screened for MBL production by imipenem disk diffusion test, 39 isolates (56%) were imipenem resistant and rest 31 (44%) were sensitive to imipenem.

All 21 *P. aeruginosa* strains showing resistance to imipenem 10 µg disk in screening test, were further tested by disk synergy test & combined disk test.

**Table.No. 1: Distribution of *P. aeruginosa* in hospital wards.**

Sources of <i>P. aeruginosa</i> isolates	Number of isolates (n=70)	Percentage
General surgery	29	41.4
Orthopedic	12	17.1
ENT	7	10
ICU	5	7.1
General medicine	5	7.1
Tb and chest disease	4	5.7
OBG & GYN	3	4.2
Pediatric surgery	3	4.2
Urology	2	2.8

**Table.No. 2: Distribution of isolates in clinical samples**

Clinical samples	Number of isolates (n=70)	Percentage
Pus	28	40
Sputum	12	17
Pus aspiration	9	12.8
Et secretion	7	10
Urine	6	8.5
Bronchial aspiration	5	7.1
Vaginal swab	3	4.2

**Table 3: Gender distribution of patients infected with *Ps. Aeruginosa*.**

Gender	Number of isolates (n=70)	Percentage
Male	58	82.8
Female	12	17

**Table 4: Imipenim resistance in *P.aeruginosa* strains.**

Antibiotics	Number of isolates (n=70)	Percentage
Imipenem sensitive	31	44
Imipenem resistance	39	56

**Table 5: Comparison of disk synergy test & combined disk test for detection of MBL producing strains.**

Test method	Number of isolates (n=70)	Percentage
Imipenem +EDTA combind disk test	21	30
Disk synergy test	10	14.2

## DISCUSSION

Our study aimed to assess the prevalence of Metallo-β-lactamase (MBL) generation in *Pseudomonas*

*aeruginosa* isolates, determine their antibiotic sensitivity patterns, and evaluate associated mortality among infected patients. Additionally, we compared various

phenotypic techniques for detecting MBL production in *P. aeruginosa*. Our study provide a comprehensive overview of the distribution of *P. aeruginosa* in different hospital wards, clinical samples, gender distribution of infected patients, and the resistance profile to imipenem.

Our study illustrates the distribution of *P. aeruginosa* isolates across various hospital wards. The highest number of isolates was found in the General Surgery ward (41.4%), followed by Orthopedic (17.1%) and ENT (10%) wards [18-19]. This highlights a significant prevalence of *P. aeruginosa* infections in surgical departments. In India, prevalence rate of *P. aeruginosa* infection varies from 10.5% to 30%. It ranged from 3 to 16%, in a multicentric study conducted by Ling J M et al.

Present study provides insights into the distribution of *P. aeruginosa* isolates in different clinical samples. Pus and exudates were the most common sources of isolates (40%), followed by sputum (17%) and pus aspiration (12.8%). This emphasizes the predilection of *P. aeruginosa* for wound and respiratory tract infections [20-21]. *P. aeruginosa* were predominantly isolated from pus (47.11%), followed by sputum sample (36.53%). The same has been reported with Okon et al., (39.2%) [6], & VijayaChaudhari et al., (35.3%). A recent study from Tehran, Iran has reported a very high prevalence of 94.2% Metallo-beta-lactamases producing *P. aeruginosa* in burn patients.

Our study reveals a notable gender disparity among patients harboring *P. aeruginosa* infections, with 82.8% being male and only 17% female. This observation suggests a potential gender-associated susceptibility to *P. aeruginosa* infections, warranting further investigation [22-23].

The resistance profile of *P. aeruginosa* strains to imipenem. Among the 70 isolates, 56% demonstrated resistance to imipenem, while 44% remained sensitive. Intriguingly, all imipenem-resistant strains were recovered from male patients, indicating a potential gender-specific resistance pattern [24-25].

Our study compares two phenotypic techniques for detecting MBL-producing strains: Imipenem + EDTA combined disk test and Disk Synergy test. Among the tested isolates, 30% were positive for MBL production using the combined disk test, while 14.2% were positive with the Disk Synergy test [26-27]. This highlights the importance of choosing appropriate methods for accurate detection of MBL production. Hemlatha et al. (2005) from India reported that 16% of *P. aeruginosa* isolates

were resistant to imipenem and 14% were positive for MBL production by combined disk test (Hemlatha et al., 2005). Behera et al. (2008) found 14.47% of *P. aeruginosa* resistant to imipenem and 10.53% positive for MBL production by combined-disk test. Behera et al. (2008) reported 7.2% imipenem resistance and 4.4% MBL positivity by combined-disk test among *P. aeruginosa* isolates (Berges et al., 2007).

The observed high prevalence of *P. aeruginosa* infections in surgical wards, particularly among male patients, underscores the importance of stringent infection control measures in these settings. The resistance of *P. aeruginosa* strains to imipenem raises concerns about the limited efficacy of this crucial antibiotic. The gender disparity in infection rates prompts further research to explore underlying factors contributing to susceptibility [9,13,15].

Furthermore, the variation in MBL detection rates between the tested methods emphasizes the need for standardized and reliable techniques in clinical settings. The findings from this study can guide clinicians in selecting appropriate diagnostic approaches and contribute to the development of targeted therapeutic strategies, ultimately improving patient outcomes and reducing the impact of *P. aeruginosa* infections in hospital settings.

It is essential to acknowledge certain limitations, such as the single-center nature of the study and the need for a larger, multicenter investigation to validate the findings. Future research should explore the molecular mechanisms underlying imipenem resistance and evaluate the clinical outcomes associated with MBL-producing *P. aeruginosa* infections. These insights are crucial for refining treatment strategies and minimizing the morbidity and mortality associated with these infections.

## CONCLUSION

Our study provides valuable insights into the epidemiology, resistance patterns, and detection methods of *P. aeruginosa* infections. These findings contribute to the ongoing efforts to optimize clinical management strategies and mitigate the impact of resistant bacterial strains in healthcare settings.

## Foot note:

**Conflict of interest: None**

**Source of Funding: Nil**

## REFERENCES

1. De AS, Kumar SH, Baveja SM. (2010). Prevalence of metallo- $\beta$ -lactamase producing *Pseudomonas aeruginosa* and *Acinetobacter* species in intensive care areas in a tertiary care hospital. Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine, 14(4), 217.

2. Kumar SH, De Anuradha S, Baveja SM, Gore MA. (2012). Prevalence and risk factors of metallo  $\beta$ -lactamase producing *Pseudomonas aeruginosa* and *Acinetobacter* species in burns and surgical wards in a tertiary care hospital. *Journal of laboratory physicians*, 4(01), 039-42.
3. Irfan S, Zafar A, Guhar D, Ahsan T, Hasan R. (2008). Metallo- $\beta$ -lactamase-producing clinical isolates of *Acinetobacter* species and *Pseudomonas aeruginosa* from intensive care unit patients of a tertiary care hospital. *Indian journal of medical microbiology*, 26(3), 243-5.
4. Senthamarai S, Sivasankari S, Anitha C, Somasunder V, Kumudhavathi MS, Amshavathani SK, Venugopal V. (2014). Resistance pattern of *Pseudomonas aeruginosa* in a tertiary care hospital of Kanchipuram, Tamilnadu, India. *Journal of clinical and diagnostic research: JCDR*, 8(5), DC30.
5. Gupta V, Datta P, Chander J. (2006). Prevalence of metallo- $\beta$  lactamase (MBL) producing *Pseudomonas* spp. and *Acinetobacter* spp. in a tertiary care hospital in India. *Journal of Infection*, 52(5), 311-4.
6. Choudhary V, Pal N, Hooja S. (2019). Prevalence and antibiotic resistance pattern of metallo- $\beta$ -lactamase-producing *Pseudomonas aeruginosa* isolates from clinical specimens in a tertiary care hospital. *Journal of Mahatma Gandhi Institute of Medical Sciences*, 24(1), 19-22.
7. Shaikh S, Fatima J, Shakil S, Rizvi SM, Kamal MA. (2015). Prevalence of multidrug resistant and extended spectrum beta-lactamase producing *Pseudomonas aeruginosa* in a tertiary care hospital. *Saudi journal of biological sciences*, 22(1), 62-4.
8. Rajput A, Saxena R, Singh KP, Kumar V, Singh S, Gupta A, Singh RK. (2010). Prevalence and antibiotic resistance pattern of metallo- $\beta$ -lactamase-producing *Pseudomonas aeruginosa* from burn patients—experience of an Indian Tertiary Care Hospital. *Journal of burn care & research*, 31(2), 264-8.
9. Radhika A, Lakshmi JT, Ariyanachi K, Sakthivadivel V. (2021). Detection of Metallo Beta-Lactamase (MBL) Producing *Pseudomonas aeruginosa* in a Tertiary Care Hospital, Ghanpur, Medchal, India. *Maedica*, 17(1), 134.
10. DardiCharanKaur D, Wankhede SV. (2013). A study of Biofilm formation & Metallo- $\beta$ -Lactamases in *Pseudomonas aeruginosa* in a tertiary care rural hospital. *Blood*, 13(3), 23-07.
11. Maharjan N. (2021). *Pseudomonas aeruginosa* Isolates among Clinical Samples showing Growth in a Tertiary Care Centre: A Descriptive Cross-sectional Study. *JNMA: Journal of the Nepal Medical Association*, 60(252), 676.
12. Sinha S, Singh A, Verma RK, Singh DP, Kumari S. (2018). Prevalence of metallo-beta-lactamases (MBLS) producing *Pseudomonas aeruginosa* in hospitalized patients in rural tertiary care hospital in Uttar Pradesh, India. *International Journal of Research in Medical Sciences*, 6(9), 3099.
13. Zavaski AP, Barth AL, Gaspareto PB, Gonçalves AL, Moro AL, Fernandes JF, Goldani LZ. (2006). Risk factors for nosocomial infections due to *Pseudomonas aeruginosa* producing metallo- $\beta$ -lactamase in two tertiary-care teaching hospitals. *Journal of Antimicrobial Chemotherapy*, 58(4), 882-5.
14. Rajput A, Prajapati B, Chauhan B, Shah A, Trivedi T, Kadam M. (2012). Prevalence of Metallo-beta-lactamases (MBL) producing *Pseudomonas aeruginosa* in a Tertiary care Hospital. *Indian Journal of Basic & Applied Medical Research*, 1(4), 304-8.
15. Ranjan S, Banashankari GS, Babu PS. (2014). Comparison of epidemiological and antibiotic susceptibility pattern of metallo-beta-lactamase-positive and metallo-beta-lactamase-negative strains of *Pseudomonas aeruginosa*. *Journal of laboratory physicians*, 6(02), 109-13.
16. Zubair KO, Iregbu KC. (2018). Resistance pattern and detection of metallo-beta-lactamase genes in clinical isolates of *Pseudomonas aeruginosa* in a central Nigeria tertiary hospital. *Nigerian Journal of Clinical Practice*, 21(2), 176-82.
17. Varaiya A, Kulkarni N, Kulkarni M, Bhalekar P, Dogra J. (2008). Incidence of metallo beta lactamase producing *Pseudomonas aeruginosa* in ICU patients. *Indian Journal of Medical Research*, 127(4), 398-402.
18. Ilyas M, Khurram M, Ahmad S, Ahmad I. (2015). Frequency, susceptibility and co-existence of MBL, ESBL & AmpC positive *Pseudomonas aeruginosa* in Tertiary Care Hospitals of Peshawar, KPK, Pakistan. *J Pure Appl Microbiol*, 9(2):981-8.
19. Goel V, Hogade SA, Karadesai SG. (2013). Prevalence of extended-spectrum beta-lactamases, AmpC beta-lactamase, and metallo-beta-lactamase producing *Pseudomonas aeruginosa* and *Acinetobacter baumannii* in an intensive care unit in a tertiary care hospital. *Journal of the Scientific Society*, 40(1), 28-31.
20. Aggarwal S, Durlabhji P, Gupta S. (2017). Incidence of Metallo- $\beta$ -lactamase producing *Pseudomonas aeruginosa* isolates and their antimicrobial susceptibility pattern in clinical samples from a tertiary care hospital. *International Journal of Research and Review*, 4(1), 92-8.
21. Kali A, Srirangaraj S, Kumar S, Divya HA, Kalyani A, Umadevi S. (2013). Detection of metallo-beta-lactamase producing *Pseudomonas aeruginosa* in intensive care units. *The Australasian medical journal*, 6(12), 686.

22. Kaur A, Singh S. (2018). Prevalence of extended spectrum betalactamase (ESBL) and metallobetalactamase (MBL) producing *Pseudomonas aeruginosa* and *Acinetobacterbaumannii* isolated from various clinical samples. Journal of pathogens.
23. Nasrin T, Jilani MS, Barai L, Haq JA. (2010). Metallo- $\beta$ -Lactamase producing *Pseudomonas* species in a tertiary care hospital of Dhaka city. Bangladesh Journal of Medical Microbiology, 4(1), 43-5.
24. Kumar R, Srivastva P, Rishi S, Dahiya SS, Hemwani K, Nirwan PS. (2014). Detection and antimicrobial susceptibility pattern of *Pseudomonas aeruginosa* isolates in various clinical samples with special reference to metallo beta lactamase from a tertiary care hospital in Jaipur, India. National Journal of Medical Research, 4(02), 128-31.
25. Karuitha JN, Akinyi OS, Njeri MA, Marianne M. (2018). Prevalence and Antimicrobial Susceptibility Profile of Metallo- $\beta$ -Lactamase Producing *Pseudomonas aeruginosa* Isolates at Kenyatta National Hospital. Advances in Microbiology, 8(11), 885.
26. Subramaniyan JS, Sundaram JM. (2018). Occurrence of bla genes encoding carbapenem-resistant *Pseudomonas aeruginosa* and *Acinetobacterbaumannii* from Intensive Care Unit in a tertiary care hospital. Journal of Laboratory Physicians, 10(02), 208-13.
27. Kaur A, Gupta V, Chhina D. (2014). Prevalence of metallo- $\beta$ -lactamase-producing (MBL) *Acinetobacter* species in a tertiary care hospital. Iranian journal of microbiology, 6(1), 22.

**Cite this article:**

Yamuna Devi V.R, Arunachala D Edukondalu (2022). Prevalence of MBL Producing *Pseudomonas aeruginosa* in Tertiary Care Hospital. *Acta Biomedica Scientia*, 9(2), 72-77



**Attribution-NonCommercial-NoDerivatives 4.0 International**